<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159094</url>
  </required_header>
  <id_info>
    <org_study_id>DO03-21-005</org_study_id>
    <nct_id>NCT00159094</nct_id>
  </id_info>
  <brief_title>A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hematology Oncology Consultants</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hematology Oncology Consultants</source>
  <brief_summary>
    <textblock>
      This is a phase II trial of Doxil on day 1 and vinorelbine on days 1 and 2 in women with&#xD;
      metastatic breast cancer. Administered every 28 days. A study to assess the safety and&#xD;
      efficacy of Doxil and vinorelbine in metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL SUMMARY&#xD;
&#xD;
      Study design: Phase II trial of monthly Doxil® and vinorelbine on day 1 and 2 in women with&#xD;
      metastatic breast cancer.&#xD;
&#xD;
      Treatment plan: Patients will continue therapy, until they have unacceptable toxicity or&#xD;
      disease progression.&#xD;
&#xD;
      Primary endpoint: Response rate&#xD;
&#xD;
      Secondary endpoints: Time to progression, overall survival and toxicity.&#xD;
&#xD;
      Additional study objectives: Evaluation of treatment-related dyspnea, with measurement of&#xD;
      pulse oximetry during and after drug administration, and rigorous study of patients who&#xD;
      experience dyspnea. Palmar-plantar erythrodysesthesia (PPE) will be treated with one of 2&#xD;
      randomly assigned topical salves, measuring duration and severity of symptoms.&#xD;
&#xD;
      Eligibility: Women who have had prior chemotherapy in the adjuvant or metastatic setting, or&#xD;
      both, up to 3 prior regimens. Patients having more than one prior regimen for metastatic&#xD;
      disease must have a performance status of 0 or 1; others may have 0-2. No prior Doxil® or&#xD;
      vinorelbine therapy. Patients are ineligible if prior anthracycline dose is greater than 400&#xD;
      mg/m2, or if they have primary anthracycline-refractory disease, with disease progression&#xD;
      during treatment or with relapse/recurrence within 6 months after last dose of anthracycline.&#xD;
      Patients must have normal neurologic, hematologic, renal and hepatic functional parameters.&#xD;
      Asymptomatic brain metastases are permissible.&#xD;
&#xD;
      Treatment plan: Doxil® 40 mg/m2 IV infusion over 60 minutes on day 1 Vinorelbine 15 mg/m2 IV&#xD;
      over 6 minutes on days 1 and 2 Dexamethasone 4 mg IV or 8 mg po (Doxil® pretreatment) Heparin&#xD;
      5000 U IV (Vinorelbine pretreatment) Pyridoxine (vitamin B6) 200 mg po qd Repeat every 28&#xD;
      days.&#xD;
&#xD;
      Supportive measures:&#xD;
&#xD;
      For anemia (hematocrit &lt; 35): Procrit® 40,000 U q wk For neutropenia (ANC &lt; 1,000/mm3 ):&#xD;
      Prophylactic antibiotics (Cipro® or Septra®) For all cycles after neutropenic fever/infection&#xD;
      or grade 3-4 stomatitis: Prophylactic Neulasta® 6 mg SQ on day 3 (This intervention may be&#xD;
      adopted for all patients, all cycles, if 2 of the first 4 patients enrolled need it.) For&#xD;
      PPE: randomize between 2 topical salves and document duration and severity of sx&#xD;
&#xD;
      Dose adjustments: Subsequent cycles are given on day 29 or after recovery or to grade 0-1&#xD;
      toxicity, with no more than 3 weeks delay. Reduce dose of both drugs by 25% if grade 3 or 4&#xD;
      stomatitis or palmar-plantar or grade 4 thrombocytopenia. Reduce dose of Doxil® ONLY by&#xD;
      50-75% if abnormal bilirubin, alkaline phosphatase and/or ALT, AST (appendix 14.3)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxil and Vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be informed of the investigational nature of this study and must give&#xD;
             and sign informed consent in compliance with federal and institutional guidelines.&#xD;
&#xD;
          -  Women 18 years or older with biopsy proven advanced breast cancer.&#xD;
&#xD;
          -  Patients with reproductive potential must use an adequate contraceptive method (e.g.,&#xD;
             abstinence, intrauterine device, oral contraceptives, barrier device with spermicide,&#xD;
             or surgical sterilization) during treatment and for three months after completing&#xD;
             treatment.&#xD;
&#xD;
          -  Performance status (PS) 0-2 (ECOG). PS must be 0-1 if patient has had more than one&#xD;
             prior regimen for metastatic disease or more than 2 prior regimens, including adjuvant&#xD;
             and metastatic.&#xD;
&#xD;
          -  Measurable disease by RECIST criteria, with baseline staging completed within 14 days&#xD;
             of registration.&#xD;
&#xD;
          -  At least two weeks post surgery and three weeks from completion of irradiation and&#xD;
             recovered from toxicities associated with these treatments.&#xD;
&#xD;
          -  Psychological, family, social and geographical conditions allowing weekly medical&#xD;
             follow up during chemotherapy are required.&#xD;
&#xD;
          -  Preregistration blood work must include complete blood counts with differential, and&#xD;
             blood chemistries including serum bilirubin, GGT, LDH, SGOT, SGPT, alkaline&#xD;
             phosphatase, creatinine, and tumor markers, CEA and CA 27-29. Patients must have:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt;1,500/mm3&#xD;
&#xD;
               -  Platelet count &gt;100,000/mm3&#xD;
&#xD;
               -  Hemoglobin &gt; 8.0 g/dl&#xD;
&#xD;
               -  Serum creatinine &lt; 2.5 mg/dl (&lt; 200 mol/L)&#xD;
&#xD;
               -  Serum bilirubin &lt; the upper limit of normal (ULN)&#xD;
&#xD;
               -  SGOT and SGPT or AST and ALT &lt; 2.0 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 2.0 x ULN, except if attributed to tumor&#xD;
&#xD;
               -  Life expectancy &gt; than 12 week.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior Doxil® or vinorelbine&#xD;
&#xD;
          -  Cumulative anthracycline dose exceeding 400 mg/m2 anthracycline&#xD;
&#xD;
          -  Primary anthracycline refractory disease, ie. disease progression during treatment or&#xD;
             relapse/recurrence within 6 months after last dose of anthracycline&#xD;
&#xD;
          -  If PS 0-1, more than 3 prior chemotherapy regimens, including adjuvant and metastatic&#xD;
&#xD;
          -  If PS 2, more than 1 prior regimen for metastatic disease or more than 2 prior&#xD;
             chemotherapy regimens, including adjuvant and metastatic&#xD;
&#xD;
          -  Hormone therapy including aromatase inhibitors within 2 weeks of baseline&#xD;
&#xD;
          -  Pregnant or lactating women. Women of reproductive potential must have a negative&#xD;
             pregnancy test and must agree to use an effective contraceptive method&#xD;
&#xD;
          -  Prior history of cardiac disease, with New York Heart Association Class II or greater,&#xD;
             or clinical evidence of congestive heart failure&#xD;
&#xD;
          -  Symptomatic brain metastasis&#xD;
&#xD;
          -  Past medical history of severe hypersensitivity reaction to conventional formulation&#xD;
             of doxorubicin HCL or the components of Doxil® or vinorelbine&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie R Laufman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Oncology Consultants, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie R Laufman, MD</last_name>
    <phone>614-846-0044</phone>
    <email>email@hoci.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology Oncology Consultants, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Conover, RN</last_name>
      <phone>614-846-0044</phone>
      <phone_ext>3104</phone_ext>
      <email>debbie@hoci.org</email>
    </contact>
    <investigator>
      <last_name>Leslie R Laufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harris Spiridonidis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjay Yadav, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Consultants, Inc</name>
      <address>
        <city>Newark</city>
        <state>Ohio</state>
        <zip>43055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Meek</last_name>
      <phone>740-344-5705</phone>
      <phone_ext>3312</phone_ext>
      <email>heather@hoci.org</email>
    </contact>
    <investigator>
      <last_name>Leslie R Laufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harris Spiridonidis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjay Yadav, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>May 30, 2008</last_update_submitted>
  <last_update_submitted_qc>May 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

